Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

Right arrow Help viewing high resolution images
Right arrow Return to article

Please click here to obtain permission to reproduce this image.

Click on image to view larger version.



Figure 2 Morphological and histological assessment of the cardiac effects of phenylephrine (PE) treatment in transgenic mice with cardiac targeted overexpression of the wild-type {alpha}1B-AR (Tg{alpha}43) and nontransgenic littermate control (NLC) mice. (A) Morphology of two Tg{alpha}43 littermates that were either phosphate-buffered saline (left) or PE (right) treated for 14 days. The heart of the sham phosphate-buffered saline treated Tg{alpha}43 mouse is indistinguishable from a phosphate-buffered saline-treated NLC mouse (not shown). However, as shown on the right, PE treatment increases the size of cardiac chambers, including left and right atria in Tg{alpha}43 mice. (B) Magnified section of a PE-treated Tg{alpha}43 heart showing an enlarged left atria with the presence of thrombi, which was seen in >60% of the PE-treated Tg{alpha}43 mice. (C) Masson trichrome stained section of a representative phosphate-buffered saline treated (sham) NLC mouse taken from the left ventricular wall toward the apex. (D) A similar section taken from a PE-treated (14 days) NLC mouse. (E) A stained section from a sham-treated Tg{alpha}43 mouse showing no fibrosis. (F) Representative left ventricular section from a PE-treated (14 days) Tg{alpha}43 mouse showing significant deposition of collagen and fibrosis (staining blue), which was seen in all Tg{alpha}43 animals after PE.





Right arrow Return to article

 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement